RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

BackgroundBladder cancer with high expression of human epidermal growth factor receptor-2 (HER2) is related to pathological malignancy and poor prognosis. The standard care for muscle-invasive urothelial bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) with...

Full description

Bibliographic Details
Main Authors: Feng Wen, Tianhai Lin, Peng Zhang, Yali Shen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
neoadjuvant treatment
HER2
muscle-invasive urothelial bladder cancer
RC48-ADC
tislelizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1233196/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1233196/full

Similar Items